Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year High – Here’s Why
by Michael Walen · The Markets DailyIntegra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) shares hit a new 52-week high during trading on Monday . The company traded as high as $18.30 and last traded at $17.61, with a volume of 2322863 shares. The stock had previously closed at $17.58.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on IART shares. Truist Financial decreased their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $11.00 to $16.00 in a report on Thursday, May 28th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Thursday. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and a consensus price target of $16.20.
Read Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Trading Up 0.5%
The stock’s fifty day simple moving average is $14.08 and its 200 day simple moving average is $12.35. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $1.38 billion, a PE ratio of -2.74, a PEG ratio of 1.22 and a beta of 1.24.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in IART. Global Retirement Partners LLC bought a new position in Integra LifeSciences in the fourth quarter worth about $25,000. Osaic Holdings Inc. lifted its position in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC grew its holdings in Integra LifeSciences by 145.9% in the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Integra LifeSciences during the 4th quarter valued at $124,000. 84.78% of the stock is owned by institutional investors.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.